Literature DB >> 23776238

B-cell maturation antigen is modified by a single N-glycan chain that modulates ligand binding and surface retention.

Han-Wen Huang1, Chein-Hung Chen, Chun-Hung Lin, Chi-Huey Wong, Kuo-I Lin.   

Abstract

Glycosylation, an important posttranslational modification process, can modulate the structure and function of proteins, but its effect on the properties of plasma cells is largely unknown. In this study, we identified a panel of glycoproteins by click reaction with alkynyl sugar analogs in plasma cells coupled with mass spectrometry analysis. The B-cell maturation antigen (BCMA), an essential membrane protein for maintaining the survival of plasma cells, was identified as a glycoprotein exhibiting complex-type N-glycans at a single N-glycosylation site, asparagine 42. We then investigated the effect of N-glycosylation on the function of BCMA and found that the dexamethasone-induced apoptosis in malignant plasma cells can be rescued by treatment with BCMA ligands, such as a proliferation-inducing ligand (APRIL) and B-cell-activating factor (BAFF), whereas removal of terminal sialic acid on plasma cells further potentiated the ligand-mediated protection. This effect is associated with the increased surface retention of BCMA, leading to its elevated level on cell surface. In addition, the α1-3,-4 fucosylation, but not the terminal sialylation, assists the binding of BCMA with ligands in an in vitro binding assay. Together, our results highlight the importance of N-glycosylation on BCMA in the regulation of ligand binding and functions of plasma cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23776238      PMCID: PMC3704023          DOI: 10.1073/pnas.1309417110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway.

Authors:  Catherine Kern; Jean-Francois Cornuel; Christian Billard; Ruoping Tang; Danielle Rouillard; Virginie Stenou; Thierry Defrance; Florence Ajchenbaum-Cymbalista; Pierre-Yves Simonin; Sophie Feldblum; Jean-Pierre Kolb
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

2.  TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease.

Authors:  J A Gross; J Johnston; S Mudri; R Enselman; S R Dillon; K Madden; W Xu; J Parrish-Novak; D Foster; C Lofton-Day; M Moore; A Littau; A Grossman; H Haugen; K Foley; H Blumberg; K Harrison; W Kindsvogel; C H Clegg
Journal:  Nature       Date:  2000-04-27       Impact factor: 49.962

3.  Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells.

Authors:  Amanda F Swindall; Susan L Bellis
Journal:  J Biol Chem       Date:  2011-05-05       Impact factor: 5.157

4.  Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.

Authors:  Anne J Novak; Jaime R Darce; Bonnie K Arendt; Brandon Harder; Kathy Henderson; Wayne Kindsvogel; Jane A Gross; Philip R Greipp; Diane F Jelinek
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

Review 5.  Oligosaccharide specificity of galectins: a search by frontal affinity chromatography.

Authors:  Jun Hirabayashi; Tomomi Hashidate; Yoichiro Arata; Nozomu Nishi; Takanori Nakamura; Mitsuomi Hirashima; Tadasu Urashima; Toshihiko Oka; Masamitsu Futai; Werner E G Muller; Fumio Yagi; Ken-ichi Kasai
Journal:  Biochim Biophys Acta       Date:  2002-09-19

6.  BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

Authors:  Jérôme Moreaux; Eric Legouffe; Eric Jourdan; Philippe Quittet; Thierry Rème; Cécile Lugagne; Philippe Moine; Jean-François Rossi; Bernard Klein; Karin Tarte
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

Review 7.  The TNF family members BAFF and APRIL: the growing complexity.

Authors:  Fabienne Mackay; Christine Ambrose
Journal:  Cytokine Growth Factor Rev       Date:  2003 Jun-Aug       Impact factor: 7.638

8.  Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival.

Authors:  Anne J Novak; Richard J Bram; Neil E Kay; Diane F Jelinek
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

9.  A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth.

Authors:  P Rennert; P Schneider; T G Cachero; J Thompson; L Trabach; S Hertig; N Holler; F Qian; C Mullen; K Strauch; J L Browning; C Ambrose; J Tschopp
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

10.  BCMA is essential for the survival of long-lived bone marrow plasma cells.

Authors:  Brian P O'Connor; Vanitha S Raman; Loren D Erickson; W James Cook; Lehn K Weaver; Cory Ahonen; Ling-Li Lin; George T Mantchev; Richard J Bram; Randolph J Noelle
Journal:  J Exp Med       Date:  2004-01-05       Impact factor: 14.307

View more
  7 in total

1.  Negative feedback regulation of Wnt signaling via N-linked fucosylation in zebrafish.

Authors:  Lei Feng; Hao Jiang; Peng Wu; Florence L Marlow
Journal:  Dev Biol       Date:  2014-09-18       Impact factor: 3.582

2.  B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.

Authors:  Yu-Tzu Tai; Kenneth C Anderson
Journal:  Expert Opin Biol Ther       Date:  2019-07-11       Impact factor: 4.388

3.  APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

Authors:  Yu-Tzu Tai; Chirag Acharya; Gang An; Michele Moschetta; Mike Y Zhong; Xiaoyan Feng; Michele Cea; Antonia Cagnetta; Kenneth Wen; Hans van Eenennaam; Andrea van Elsas; Lugui Qiu; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2016-04-28       Impact factor: 22.113

Review 4.  Non-classical B Cell Memory of Allergic IgE Responses.

Authors:  Sean P Saunders; Erica G M Ma; Carlos J Aranda; Maria A Curotto de Lafaille
Journal:  Front Immunol       Date:  2019-04-26       Impact factor: 7.561

Review 5.  B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages.

Authors:  Shirin Teymouri Nobari; Jafar Nouri Nojadeh; Mehdi Talebi
Journal:  J Transl Med       Date:  2022-02-10       Impact factor: 5.531

6.  Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses.

Authors:  John Daly; Subhashis Sarkar; Alessandro Natoni; Jessica C Stark; Nicholas M Riley; Carolyn R Bertozzi; Mattias Carlsten; Michael E O'Dwyer
Journal:  Blood Adv       Date:  2022-06-14

Review 7.  Approaches for Controlling Antibody-Mediated Allograft Rejection Through Targeting B Cells.

Authors:  Yoshiko Matsuda; Takeshi Watanabe; Xiao-Kang Li
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.